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match in related transplant is unlikely. In contrast, investigating
the frequency of a donor-recipient HFE mismatch in a series of 60
unrelated bone marrow transplants otherwise perfectly matched on
the HLA-A,B,C,DRB1,DQB1 loci, we found a mismatch in 10
cases. These data suggest that HFE could be a potent histocom-
patibility antigen in humans in view of its structural polymorphism.
129
MULTIDISCIPLINARY APPROACH TO DEVELOPMENT OF A GVHD OUT-
PATIENT CLINIC
Yount, P.1, Vance, E.A.1, Agura, E.D.1, Berryman, R.B.1, Fay, J.W.1,
Pineiro, L.1, Bengtson, E.1, Bair, J.D.2 1. Baylor Sammons Cancer
Center and Texas Oncology, P.A., Dallas, TX; 2. Baylor University
Medical Center, Dallas, TX.
Managing GVHD is a particularly challenging aspect of the care
of blood and marrow transplant recipients. In the Blood and
Marrow Transplant program at Baylor University Medical Center,
the GVHD patients were identiﬁed as a population that could
beneﬁt from an interdisciplinary approach in a specialized clinic
setting. A questionnaire was sent to the transplant physician group
to gauge interest in and the need for this clinic. It was determined
that enough interest was present and a patient population would
support the organization of this program. The interdisciplinary
team consisted of an oncologist as team leader, dermatologist,
clinic manager, contract administrator, nurse manager, pharmacist,
biostatistician, physical therapist, occupational therapist, dietitian,
enterostomal therapist, social worker, and chaplain. The team
gathered for regular meetings to decide on structure, services, and
supplies that would be needed to support such an endeavor. The
clinic manager and contract administrator investigated ﬁnancial
reimbursement for each discipline in the outpatient setting. Orga-
nization of the GVHD clinic recommended that each patient see
the medical team leader followed by other specialty areas that
would beneﬁt the patient. A key component for a successful clinic
is data collection for patients before their appointments to assist
clinicians with a thorough needs assessment. Each discipline of-
fered a data collection tool and these were compiled by a team
member. This tool includes sections on medication, medical symp-
toms, skin assessment, nutrition, physical and occupational ther-
apy, and psychosocial needs. Prior to patient’s appointments, ques-
tionnaires are mailed with the instructions to complete and bring
to their appointment. Research protocols for disciplines in this
clinic are being developed. Taking a multidisciplinary approach to
a GVHD clinic is a key factor in developing a successful program.
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IL-7 IS NECESSARY FOR THE DEVELOPMENT OF EXPERIMENTAL
GRAFT-VERSUS-HOST DISEASE (GVHD)
Chung, B., Dudl, E.P., Toyama, A., Barsky, L., Price, M., Weinberg,
K.I. Childrens Hospital Los Angeles, Los Angeles, CA.
Interleukin 7 (IL-7) promotes both thymopoiesis and the survival
and proliferation of mature T lymphocytes. Although IL-7 en-
hances immune reconstitution following hematopoietic stem cell
transplantation (HSCT), its effect on mature T lymphocytes in
allogeneic bone marrow transplantation (BMT) could lead to ex-
acerbation of GVHD. However, recent experiments to determine
whether IL-7 treatment worsens GVHD have produced conﬂict-
ing results. Therefore, this study was designed to examine whether
IL-7 is necessary for the induction of GVHD by maintaining
donor mature T cells following allogeneic BMT. In order to
induce GVHD, B6 or B6/IL-7
/
 (CD45.2 H2Kb) recipient
mice were lethally irradiated (1300 cGy) and co-transplanted with
4x106 lymph node (LN) and 1x106 T cell depleted (TCD) BM cells
from either congenic B6.SJL (CD45.1, H2Kb) or major MHC
mismatched allogeneic Balb/C (CD45.2, H2Kd) donor mice. Fol-
lowing transplantation, the recipient mice received either human
recombinant IL-7 (rhIL-7) 500ng BID or PBS from day 1 to 60.
The survival rate was similar in all groups of mice for the ﬁrst 25
days after transplantation and no evidence of GVHD was detected
from allogeneically transplanted B6/IL-7
/
 recipients treated
with PBS. In contrast, GVHD-related mortality and morbidity in
allogeneic recipients treated with IL-7 were increased compared to
the PBS treated groups. IL-7 treatment signiﬁcantly reduced sur-
vival in the B6/IL-7
/
 mice (15%, n  20) compared to the PBS
treated B6/IL-7
/
 recipients (59%, n 17 [p 0.005]). Further-
more, the overall GVHD clinical index of IL-7 treated B6/IL-7
/

was signiﬁcantly lower than the PBS treated B6/IL-7
/
 recipients
(p  0.05). The recovery of donor CD4 or CD8 T cells in the
periphery of the PBS treated B6/IL-7
/
 recipients was signiﬁ-
cantly lower than the IL-7 treated B6/IL-7
/
 mice by day 30
post-transplantation. In addition, IL-7 treatment increased the
number of activated (CD69 positive) donor-derived CFSE labeled
CD4 and CD8 LN T lymphocytes in the lymph nodes of B6/IL-
7
/
 mice compared to PBS treated B6/IL-7
/
 recipients indi-
cating that IL-7 enhances maintenance of dividing activated al-
logneic mature T cells. Therefore, it is likely that IL-7 is necessary
for the development of GVHD presumably by maintaining the
adequate number of activated donor T cells in the periphery of the
recipient animals post-allogeneic BMT.
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THE ABSENCE OF PEYER’S PATCHES OR HOST TNF- DOES NOT
AFFECT GVHD PROGRESSION IN AN ALLOGENEIC BMT MODEL USING
EXTENSIVE CONDITIONING REGIMENS
Welniak, L.A.1, Kuprash, D.V.2, Tumanov, A.V.2, Sun, K.1, Stull,
S.W.2, Anver, M.R.2, Nedospasov, S.A.2, Murphy, W.J.1 1. University
of Nevada, Reno, Reno, NV; 2. SAIC-Frederick, Frederick, MD.
Peyer’s patches (PP) have been previously shown to play a critical
role in the initiation of acute lethal GVHD in a non-irradiated
murine model (Murai et al., 2003). This report utilized IL-7
receptor antibody treatment of pregnant mice to inhibit the devel-
opment of PPs in the fetus. We wanted to assess GVHD progres-
sion in mice congenitally deﬁcient in PP presence and function.
The absence of various members of the TNF and TNF-R families
also affects secondary lymphoid structure and organization. The
presence of PP has varied between different independently gener-
ated TNF knockout strains which may be related to the close
linkages of tnf with lta and ltb genes. A new TNF deﬁcient strain
has been developed that lacks PPs, displays the defects character-
istic of TNF ablation but not the LT associated defects character-
ized by lack of lymph nodes and defects in splenic microarchitec-
ture. To examine the role of host-derived TNF family members in
acute lethal GVHD, we also had to assess the role of secondary
lymphoid structures. We utilized a full MHC mismatched mode of
BALB/c (H2d) cells into myeloablated C57BL/6 (H2b) recipients.
We lethally irradiated wild type (WT) mice, TNF- deﬁcient mice
with Peyer’s patches (PP) and TNF- deﬁcient mice without
Peyer’s patches (PP-) followed by infusion of allogeneic bone
marrow and spleen cells. We observed no difference in the survival
of the three groups of mice (median day of death ranged from 26
to 27). In addition, no signiﬁcant differences were observed in
GVHD associated histopathological lesions in the small intestine.
Hisopathological lesions observed in the colon were similar in both
the PP and PP- TNF- deﬁcient recipients. Based on our ob-
servations, we conclude that (1) Peyer’s patches and (2) host
TNF- are not required for the development of acute lethal
GVHD in mice that received extensive conditioning and allogeneic
bone marrow transplantation.
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DEVELOPMENT OF NUTRITION ALGORITHMS FOR CHRONIC GVHD
Bair, J.D.1, Roberts, S.R.1, Thompson, J.1, Agura, E.D.2, Berryman,
R.B.2, Fay, J.W.2, Pineiro, L.2, Vance, E.A.2 1. Baylor University
Medical Center, Dallas, TX; 2. Baylor Sammons Cancer Center and
Texas Oncology, P.A., Dallas, TX.
One of the challenges for patients with chronic GVHD is to
maximize quality of life by maintaining optimal nutritional intake
and minimizing loss of lean body mass. Registered Dietitians
(RD’s) play an integral role in the nutritional care of patients in the
Blood and Marrow Transplant program at Baylor University Med-
ical Center and are part of the team establishing a new GVHD
clinic. Patients referred to the GVHD clinic are seen by the RD
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and a Patient Generated Subjective Global Assessment (PG-SGA)
is used to assess overall nutritional risk. The RD assesses the
macro- and micronutrient adequacy and tolerance of each patient’s
diet. Nutrition standards of care include counseling by the RD on
individual calorie, protein, and vitamin/mineral requirements and
how best to achieve these goals. At our institution three RD’s
provide care in the GVHD clinic. In order to standardize care
across the RD’s and to facilitate communication with the interdis-
ciplinary team, nutrition algorithms were developed. The RD’s
reviewed each of the most common types of GVHD with nutri-
tional implications. They were divided into ﬁve main focuses: 1)
Upper GI (oral/esophageal) GVHD; 2) Lower GI and Liver
GVHD (large volume diarrhea); 3) Anorexia/Failure to Thrive; 4)
Skin GVHD; 5) High Dose Steroid Use. The algorithms are a
series of interventions organized based on such factors as patient’s
ability to eat, adequacy of diet, weight loss, and GI symptoms.
Initial interventions include diet education along with nutritional
and vitamin/mineral supplementation. If these are unsuccessful,
pharmacological interventions and nutrition support via either an
enteral or parenteral route are instituted. Current plans include a
research protocol to evaluate preservation of lean body mass and
improvement in quality of life when nutrition algorithms are fol-
lowed in chronic GVHD patients.
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A MULTI-INSTITUTIONAL STUDY OF EXTRACORPOREAL PHOTO-
PHORESIS (ECP) WITH UVADEX FOR THE PREVENTION OF ACUTE
GRAFT VS. HOST DISEASE (AGVHD) IN PATIENTS (PTS) UNDERGOING
ALLOGENEIC HEMATOPOIETIC PROGENITOR CELL TRANSPLANTS
(ALLO-HPCT) WITH MYELOABLATIVE CONDITIONING
Abhyankar, S.1, Bolwell, B.J.2, Shaughnessy, P.J.3, van Besien, K.4,
Ilhan, O.5, Machado, A.6, Dodds, A.7, Grigg, A.8, Prince, H.M.9,
Mistrik, M.10, Gruben, D.11, Thienel, U.11 1. Kansas City Cancer
Center, Kansas City, MO; 2. The Cleveland Clinic Foundation, Cleve-
land, OH; 3. Texas Transplant Institute, San Antonio, TX; 4. Univer-
sity of Chicago, Chicago, IL; 5. Ankara University Medical School,
Ankara, Turkey; 6. Instituto Portugues de Oncologia de Francisco Gentil,
Lisbon, Portugal; 7. St Vincent’s Hospital, Sydney, Australia; 8. Royal
Melbourne Hospital, Melbourne, Australia; 9. Peter MacCallum Cancer
Institute, East, Melbourne, Australia; 10. Klinika Hematologie a Trans-
fuziologie, Bratislavia, Slovakia (Slovak Republic); 11.Clinical Develop-
ment, Therakos, Inc, Exton, PA; 12. The Photopheresis Study Group,.
GvHD remains a major cause of morbidity and mortality after an
allo-HPCT, and ECP has been shown in numerous studies to be
effective in its treatment. ECP has also been used in the prevention
of GvHD in a novel non-myeloablative preparative regimen for
allo-HPCT (Foss, BBMT 9:96, 2003). The incidence of aGvHD
was substantially reduced in this study, possibly due to the effect of
ECP on host dendritic cells, causing alteration in allo-antigen
presentation and reduced donor T-cell activation. We report here
the preliminary results of a multi-institutional phase II study uti-
lizing ECP with Uvadex® in a myeloablative regimen of allo-
HPCT. Treatment with ECP was given on any two days from Day
–10 to –6, followed by cyclophosphamide 60mg/kg for 2 days and
TBI 1200 cGy over three days. Pts. received cyclosporine (CSA)
3-5mg/kg iv from Day –1 (and switched later to PO), to keep levels
between 200-600 ng/ml, and methotrexate 10mg/m2 on Days 1,3,6
and 11 for matched unrelated donors (MUD) and one antigen
mismatched related donors, and 10mg/m2 on Day 1 and 5mg/m2
on Days 3,6 and 11 in matched related donors (MRD), as GvHD
prophylaxis. CSA was continued until Day 100 and then tapered.
Data is available on 34 of 50 enrolled pts. Nineteen pts. are male
and the median age is 37 (range 20 –58). Diagnosis leading to
HPCT includes acute leukemia and myelodysplasia (n  21),
chronic leukemia (n  9), lymphoma (n  3) and other (n  1).
Eighteen pts. received bone marrow (BM) and 16 peripheral blood
(PB) HSCT. Nineteen pts. received matched unrelated or mis-
matched related grafts and 15 matched related. Median time to
engraftment was 20 days for BM and 15 days for PB. ECP was well
tolerated in 33 pts. with one pt. having mild reversible hypoten-
sion. ECP was not discontinued on any pt. At a median follow up
of 85 days (range 5 to 295), acute GvHDGrade II–IV developed in
11 (35.5%) pts. (6 with BM and 5 with PB; 4 with MRD HPCT
and 7 with MUD HPCT). Three pts.died (all MUD HPCT) at a
median of 47 days from HPCT, two from aGvHD (Grades III and
IV), and one from multi-organ failure. 31 pts. are alive while 3 have
relapsed (2 with ALL and 1 NHL). This preliminary analysis
shows that ECP can safely be administered to pts. undergoing
myeloablative allo-HPCT. Further follow up is ongoing to assess
acute and chronic GvHD rates, relapse and transplant related
mortality. Pre and post–ECP lab data on T cell subsets, dendritic
cells and NK cells will also be evaluated.
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RISK FACTORS FOR SYNGENEIC GRAFT-VERSUS-HOST DISEASE IN
ADULT HEMATOPOIETIC STEM CELL TRANSPLANTS
Adams, K.M.1,2, Holmberg, L.A.1,2, Leisenring, W.1, Guthrie, K.A.1,
Tylee, T.S.2, McDonald, G.B.1,2, Bensinger, W.I.1,2, Nelson, J.L.1,2 1.
Fred Hutchinson Cancer Research Center, Seattle, WA; 2. University of
Washington, Seattle, WA.
Cutaneous, hepatic and gastrointestinal graft-versus-host disease
(GVHD) has been described after both syngeneic and autologous
stem cell transplants. The recent ﬁnding of male DNA in female
donor apheresis products and associations between parous donors
and allogeneic GVHD raise the question of whether persistent
pregnancy-derived fetal microchimerism in donors or recipients
could contribute to the development of sGVHD. Our objective
was to identify the incidence, morbidity, and risk factors for syn-
geneic GVHD (sGVHD) following hematopoietic stem cell trans-
plantation (HSCT) with analysis focused on pregnancy history of
the donor/recipient as potential risk factors. We retrospectively
reviewed the transplant outcomes of 119 adults undergoing syn-
geneic HSCT at our center between 1980 and 2002. We required
diagnostic histological ﬁndings on a biopsy of the skin, intestinal
tract, or liver for the diagnosis of sGVHD. Among 119 syngeneic
transplants, 21 patients had biopsy-proven sGVHD for a preva-
lence of 18%. The median time to developing sGVHDwas 39 days
(range 20-79). In 6 cases, biopsies conﬁrmed multi-organ involve-
ment; sGVHD was the ofﬁcial cause of death in one case. sGVHD
developed in 24% of the women and 13% of the men. A signiﬁ-
cantly higher frequency of sGVHD occurred in the context of a
parous donor (p  0.03, parous donor 11/34, 32%; nulliparous
donor 1/11, 9%; male donor 9/70, 13%) or parous recipient (p 
0.02, parous recipient 11/35, 31%; nulliparous recipient 1/14, 7%;
male recipient 9/70, 13%). Of 26 twin pairs with a parous donor
and parous recipient, 10 (38%) women developed sGVHD versus
no cases in 5 women with a nulliparous donor and recipient (p 
0.10). Other factors signiﬁcantly associated with sGVHD on uni-
variable analysis include older age (p  0.004), Busulfan/Melpha-
lan/Thiotepa conditioning (p  0.002), interleukin-2 therapy (p 
0.017), HLA-A26 type (p  0.02), and more recent transplant year
(p  0.004). In a Cox regression model based on suggestive uni-
variable predictors, only recipient parity and more recent trans-
plant year remained signiﬁcantly associated with sGVHD. The
ﬁnding of recipient parity as a risk factor for sGVHD may support
a role for fetal microchimerism in sGVHD.
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IMMUNOLOGICAL EFFECTS OF DONOR LYMPHOCYTE INFUSION IN
PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA RELAPSING AF-
TER ALLOGENEIC BONE MARROW TRANSPLANTATION
Voltarelli, J.1, Palma, P.1, Morais, F.1, Castro, F.2 1. Centro Regi2.
2Faculdade de Ciencias Farmaceuticas USP, Ribeirao Preto, State of Sao
Paulo, Brazil.
Donor lymphocyte infusion (DLI) is a very efﬁcient therapy for
relapse of chronic myelogenous leukemia in chronic phase (CP-
CML) after allogeneic bone marrow transplantation (BMT). Infu-
sion of allogeneic lymphocytes induces a graft-versus-leukemia
(GVL) effect which produces long term remission in most patients.
However, immunological mechanisms involved in this reaction are
poorly understood. We studied several immunological markers and
Poster Session I
53BB&MT
